Biotech News
aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update
investors.atyrpharma.com2026-05-06 15:06 EST
Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to determine path forward for efzofitimod in pulmonary sarcoidosis in the first quarter of 2026. Company expects to complete enrollment in Phase 2 EFZO-CONNECT™ study of